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http://dx.doi.org/10.1016/j.ccr.2012.11.003SUMMARYMALT1 cleavage activity is linked to the pathogenesis of activated B cell-like diffuse large B cell lymphoma
(ABC-DLBCL), a chemoresistant form of DLBCL. We developed a MALT1 activity assay and identified chem-
ically diverse MALT1 inhibitors. A selected lead compound, MI-2, featured direct binding to MALT1 and
suppression of its protease function. MI-2 concentrated within human ABC-DLBCL cells and irreversibly in-
hibited cleavage ofMALT1 substrates. This was accompanied by NF-kB reporter activity suppression, c-REL
nuclear localization inhibition, and NF-kB target gene downregulation. Most notably, MI-2 was nontoxic to
mice, and displayed selective activity against ABC-DLBCL cell lines in vitro and xenotransplanted ABC-
DLBCL tumors in vivo. The compound was also effective against primary human non-germinal center B
cell-like DLBCLs ex vivo.INTRODUCTION
Non-Hodgkin’s lymphoma (NHL) is the seventh most frequent
cancer (Siegel et al., 2012). Diffuse large B cell lymphoma
(DLBCL) is the most common subtype of NHL, accounting for
25% of all lymphoma cases (Swerdlow et al., 2008). Gene
expression profiling allowed subclassification of DLBCL into
distinct molecular subtypes, including germinal center B cell-Significance
MALT1 is a unique paracaspase protein that transduces abe
reports the development of a constitutively activated form of
This led to identification of MI-2, an irreversibleMALT1 proteas
in cell-based assays and selective activity against ABC-DLB
DLBCLs in vitro and in vivo, are nontoxic to animals, and also su
we demonstrate that MALT1 is a bona fide therapeutic target an
therapeutic agents for B cell lymphomas.
812 Cancer Cell 22, 812–824, December 11, 2012 ª2012 Elsevier Inclike (GCB) DLBCL, activated B cell-like (ABC) DLBCL, and
primary mediastinal B cell lymphoma (PMBL) (Alizadeh et al.,
2000; Rosenwald et al., 2003). These subtypes differ significantly
in their spectrum of recurrent somatic mutations, dependence
on different signaling pathways, and response to current stan-
dard therapies (Lenz et al., 2008b; Wright et al., 2003). Patients
with the GCB subtype have a significantly better overall survival
compared to those with the ABC subtype (Alizadeh et al., 2000;rrant oncogenic signaling in ABC-DLBCL. This manuscript
MALT1 that enabled a screen for small molecule inhibitors.
e inhibitor, which is a lead compoundwith nanomolar activity
CLs. Importantly, we show that MALT1 inhibitors kill ABC-
ppress primary human non-GCB-DLBCL specimens. Hence,
d provide a lead compound that forms the basis of a class of
.
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MALT1 Inhibitors for ABC-DLBCLRosenwald et al., 2002). Improved therapies are needed for all
DLBCLs but most urgently for ABC-DLBCLs, which are the
most chemoresistant.
ABC-DLBCL is characterized by its reliance on the oncogenic
activation of the NF-kB pathway through several different mech-
anisms. These mostly involve somatic mutations in molecules
participating in signaling downstream of the B cell receptor
(BCR), including activating mutations of CARMA1/CARD11
(Lenz et al., 2008a) and CD79A/B (Davis et al., 2010), homozy-
gous deletion/inactivating mutations of TNFAIP3/A20 (Com-
pagno et al., 2009; Honma et al., 2009), and activating mutations
ofMYD88 downstream of the Toll-like receptor (Ngo et al., 2011).
CARMA1 forms part of the CARMA1-BCL10-MALT1 (CBM)
complex and mediates NF-kB activation downstream of the B
cell receptor, T cell receptor (Ruefli-Brasse et al., 2003; Ruland
et al., 2003), and ITAM-coupled natural killer cell receptors
(Gross et al., 2008). The MALT1 (mucosa-associated lymphoid
tissue lymphoma translocation 1) subunit is the active signaling
component of the CBMcomplex (Lucas et al., 2001) and features
protease activity that cleaves and inactivates inhibitors of the
NF-kB signaling pathway such as TNFAIP3/A20 (Coornaert
et al., 2008), CYLD (Staal et al., 2011), and RELB (Hailfinger
et al., 2011) or the BCL10 protein (Rebeaud et al., 2008), indi-
rectly activating NF-kB signaling. MALT1 translocations,
including t(11;18)(q21;q21), which produces an API2-MALT1
fusion, and t(14;18)(q32;q21), which results in the IGH-MALT1
translocation, are detected in up to 55% of MALT-type
lymphomas (Farinha and Gascoyne, 2005). These translocations
lead to overexpression of MALT1 and, in the case of the API2-
MALT1 translocation, constitutive activation of the pathway
(Dierlamm et al., 1999; Sanchez-Izquierdo et al., 2003; Streubel
et al., 2003). Constitutive expression of MALT1 in mice induces
a disease that is similar to MALT lymphomas in humans, and
induces ABC-like DLBCLs in a p53-null background (Vicente-
Duen˜as et al., 2012). MALT1 has not been found mutated or
translocated in DLBCL but is gained along with BCL2, and
this low-copy-number amplification is associated with an
ABC-DLBCL phenotype (Dierlamm et al., 2008). Moreover,
ABC-DLBCL cell lines have been shown to be dependent on
MALT1 catalytic activity (Ferch et al., 2009; Hailfinger et al.,
2009; Ngo et al., 2006).
MALT1 is a paracaspase, which is related to the caspase
(cysteine-aspartic proteases) family of proteases but cleaves
after Arg residues instead of Asp (Rebeaud et al., 2008).
MALT1 is the only gene encoding paracaspase in the human
genome. MALT1-null animals display defects in B and T cell
function but are otherwise healthy (Ruefli-Brasse et al., 2003;
Ruland et al., 2003). These factors suggest that MALT1-targeted
therapy would likely be well tolerated with little or manageable
toxicity. Consequently, MALT1 represents a potentially impor-
tant therapeutic target for ABC-DLBCL and MALT lymphoma.
RESULTS
Biochemical Screening Identifies LowMolecular Weight
Inhibitors of MALT1 Proteolytic Activity
We reasoned that MALT1 small molecule inhibitors might be
useful chemical tools for studying MALT1 biology and treating
MALT1-addicted tumors. However, full length MALT1 and itsCanparacaspase domain (amino acids 340–789) are naturally
present in physiological solutions as a monomer, which has
very low proteolytic activity. Caspases generally must homodi-
merize for maximal catalytic activity (Pop et al., 2006; Walker
et al., 1994; Yin et al., 2006), and accordingly the recently
reported structures of the paracaspase domain of MALT1 in
complex with a peptide inhibitor are dimeric (Wiesmann et al.,
2012; Yu et al., 2011). In order to generate catalytically active
MALT1 for an effective assay to screen for inhibitors, we
biochemically engineered a recombinant form of MALT1 (340–
789) fused with a leucine zipper dimerization motif (LZ-MALT1),
which promotes its dimerization and activation (Figure 1A).
We developed a MALT1 activity assay using the MALT1 sub-
strate peptide LRSR linked to the fluorogen AMC (7-amino-4-
methylcoumarin). Cleavage of the Ac-LRSR-AMC substrate by
MALT1 resulted in release of AMC and a fluorescent signal.
The optimal conditions for high-throughput screening were
determined by systematic variation of the concentrations of the
enzyme and the substrate in a two-dimensional grid. Fluores-
cence measurements were taken every 45 s for 60 min. The
measurements were plotted as a function of time. Conditions
with a linear relationship between fluorescence and time were
considered appropriate for screening. Quality was assessed
using the Z0 factor, a coefficient reflective of the dynamic range
of the assay and variance of the data (Zhang et al., 1999), calcu-
lated by the formula Z0 factor = 1 33 (sp +sn)/(jmp mnj), where
sp/n is the standard deviation for positive and negative control
and mp/n is the mean for positive and negative control. The Z
0
factor for this screenwas 0.738, which is within the optimal range
0.5–1 (Zhang et al., 1999). A total of 46,464 compounds was
screened (see Supplemental Experimental Procedures available
online). Using 40% inhibition as a threshold, 324 candidate
compounds were selected for validation in a concentration-
response assay (Figure 1B). Of these, 19 compounds (Fig-
ure S1A) were selected for further validation based on their
biochemical activity (half-maximal inhibitory concentration
[IC50] < 20 mM; Figure 1C).
Candidate Inhibitors Selectively Suppress ABC-DLBCL
Cell Lines and MALT1 Catalytic Activity
MALT1 activity plays an important role in selectively maintaining
proliferation of ABC-DLBCL cell lines (Ngo et al., 2006). Accord-
ingly, ABC- and GCB-DLBCL cell lines present differential
sensitivity to MALT1 cleavage inhibition by the peptide Z-
VRPR-FMK (Ferch et al., 2009; Hailfinger et al., 2009; Rebeaud
et al., 2008). To determine whether candidate small molecules
display a similar profile, two ABC-DLBCL cell lines, HBL-1 and
TMD8, and one GCB-DLBCL cell line, OCI-Ly1, were exposed
to increasing concentrations of the 19 selected molecules. Cell
proliferation was measured 48 hr after exposure to a single
dose of compound using an ATP-based metabolic luminescent
assay (summarized in Figure 1C). Three compounds consistently
induced significant selective dose-dependent suppression of
ABC-DLBCL cells (MI-2, p < 0.0001; MI-4, p = 0.006; MI-11,
p < 0.0001; regression extra sum-of-squares F test; Figures 1C
and S1B). Hence, these compounds were active in cells, selec-
tive for ABC-DLBCLs, and lack nonspecific cellular toxicity.
MI-6 and MI-15 also showed differential inhibition of ABC-
DLBCL cells but did not reach statistical significance.cer Cell 22, 812–824, December 11, 2012 ª2012 Elsevier Inc. 813
Figure 1. Identification of MALT1 Small
Molecule Inhibitors
(A) Dimeric LZ-MALT1 representation showing
LZ-MALT1 monomers in yellow and magenta.
Met338 is shown as a sphere model. The model
was generated using the MALT1 structure (Protein
Data Bank [PDB] ID code 3UOA) and LZ structure
(PDB ID code 2ZTA).
(B) Represented is the % inhibition for each of
the compounds assayed at 12.5 mM. Cutoff was
40% inhibition.
(C) Summary table of IC50 and GI25 results for
screening hits. Experiments were performed
three times in triplicate. Fold difference = OCI-Ly1
GI25/average GI25 for the MALT1-dependent cell
lines. *Significant dose-dependent suppression
of proliferation in ABC-DLBCL, regression extra
sum-of-squares F test.
(D) MI-2 structure.
(E) MALT1 cleavage of CYLD inhibition by MI-2
in HBL-1 cells at 24 hr studied by western blot.
a-tubulin, and loading control. Densitometry
values were normalized to a-tubulin and are rela-
tive to vehicle-treated cells. The representative
result is from three experiments.
See also Figure S1.
Cancer Cell
MALT1 Inhibitors for ABC-DLBCLCompound MI-2 was the most potent in cell-based assays,
with 25% growth-inhibitory concentration (GI25) values in the
high-nanomolar range. MI-2 (Figure 1D) was therefore next as-
sayed for inhibition of MALT1-mediated substrate cleavage in
lymphoma cells. HBL-1 cells were treated with increasing
concentrations of MI-2 for 24 hr and cleavage of the MALT1
target protein CYLD was measured by western blotting and
densitometry. MI-2 caused a dose-dependent decrease
in MALT1-mediated cleavage, noted by an increase in the
uncleaved CYLD protein and a decrease in the cleaved form of
the protein (Figure 1E). MI-2 was selective as a MALT1 paracas-
pase inhibitor, because it displayed little activity against the
structurally related caspase family members caspase-3, -8,
and -9 (Figure S1C). Moreover, MI-2 did not inhibit caspase-3/7
activity or apoptosis in cell-based assays at concentrations
that suppress MALT1 (Figures S1D–S1F). Hence, MI-2 is a
potential lead compound as a therapeutic MALT1 inhibitor.
MI-2 Analogs Display MALT1-Inhibitory Activity
To establish whether compound MI-2 represented a potential
scaffold for development of MALT1 inhibitors, we compared
MI-2with other chemical compounds in silico to identify potential
analogs. A total of 704 analog compounds from available
libraries with similarity score R70% (Tanimoto similarity func-
tions) was screened by LZ-MALT1 fluorescence assay. Nineteen
analogs displaying equal or higher activity than MI-2 were814 Cancer Cell 22, 812–824, December 11, 2012 ª2012 Elsevier Inc.selected (Figure 2A). Five analogs with
biochemical IC50s within a similar range
as MI-2 were selected for further charac-
terization in cell-proliferation assays (Fig-
ures 2B and 2C). All five analogs (MI-2A1–
5) exhibited the same trend toward selec-
tive suppression of the ABC-DLBCL celllines, with GI25 concentrations in the micromolar range (Fig-
ure 2C). Two analog compounds with no LZ-MALT1-inhibitory
activity in vitro (MI-2A6 and -7) used as chemical controls had
no effect on cell proliferation over the same dose range (Fig-
ure S2). The five active MI-2 analogs were assayed for inhibition
of MALT1 cleavage of CYLD. All five compounds, administered
at 5 mM for 8 hr, showed cleavage inhibition similar to the
Z-VRPR-FMK MALT1 blocking peptide (50 mM) used as positive
control (Figure 2D), although MI-2 itself remained the most
potent compound. Collectively, the conservation of MALT1
inhibitor activity in vitro and in cell-based assays among
chemically related compounds points toward the suitability of
MI-2 and its analogs as lead compound inhibitors of MALT1.
MI-2 Directly Binds and Irreversibly Inhibits MALT1
We next investigated whether MI-2 directly bound to MALT1 or
indirectly affected MALT1 activity, for example through binding
to the LZ region of the fusion protein. Heteronuclear single-
quantum coherence (HSQC) nuclear magnetic resonance
(NMR) spectroscopy was used to characterize the binding of
MI-2 to the paracaspase domain of MALT1 (residues 329–728).
As MI-2 was titrated in, resonances corresponding to the
unbound state of MALT1 decreased in intensity, while another
set of resonances corresponding to the MALT1-MI-2 complex
gradually appeared (Figure 3A). This pattern of chemical shift
changes is characteristic of slow exchange on the NMR
Figure 2. MI-2 Analogs Display Similar
MALT1-Inhibition Activity
(A) Seven hundred and four compounds with
over 70% homology to MI-2 were screened.
Compounds with equal or higher activity than MI-2
were selected.
(B) Structures of the MI-2 analog compounds
assayed in cell growth-inhibition experiments.
Blue, active analogs; red, inactive analogs.
(C) IC50 and GI25 values for the selected analogs
assayed in HBL-1, TMD8, and OCI-Ly1 cells.
Experiments were performed three times in tripli-
cate. Fold difference = OCI-Ly1 GI25/average GI25
for the MALT1-dependent cell lines.
(D) CYLD cleavage was studied in HBL-1 cells
treated with 5 mM analog compound or 50 mM
Z-VRPR-FMK for 8 hr. Densitometry results were
normalized to a-tubulin and fold change-to-vehicle
ratios were calculated. Results are mean ± SEM
of three independent experiments.
See also Figure S2.
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MALT1 Inhibitors for ABC-DLBCLtimescale and is indicative of a robust interaction between
MALT1 and MI-2. In contrast, NMR spectroscopy studies
showed no evidence of binding by the inactive analogs MI-2A6
and MI-2A7 (Figure 3B).
Because MI-2 contains a reactive chloromethyl amide, we
investigated whether MI-2 could modify MALT1 covalently
using liquid chromatography-mass spectrometry (LC-MS). As
shown in Figure 3C, MALT1 paracaspase domain (329–728)
presented a major peak at 55,988.4 Da. Upon incubation with
the compound MI-2, the major peak of MALT1 was shifted to
56,407.5 Da, an increase of 419.1 Da. This corresponds to
addition of MI-2 minus the chloride group, indicating that MI-
2 can bind covalently to MALT1 and potentially act as an irre-
versible inhibitor. Because the chloromethyl amide group is
not conserved in the active MI-2 analogs (Figure 2B), it is
most likely the common chemical scaffold in the MI-2 series
that provides specificity to MALT1. Notably, LC-MS performed
with MI-2 and the MALT1 active site mutant C464A revealed
markedly reduced covalent binding, suggesting that the active
site C464 residue is the main target of modification by MI-2
(Figure 3C). To further explore the potential mode of binding
of MI-2 to the MALT1 paracaspase domain, we employed
molecular docking using AutoDock 4.2 (Morris et al., 2009).
The crystal structure of MALT1 (Wiesmann et al., 2012; Yu
et al., 2011) was kept as a rigid body while allowing conforma-
tional flexibility of MI-2. The final results were ranked on the
predicted binding free energy and the cluster size for each
docking conformation. The top five poses were selected, all
of which had similar docking scores with slight changes in
their orientations. As shown for the first top hit, MI-2 appearsCancer Cell 22, 812–824, Dto bind the active site cleft with its
chloromethyl group close to the active
site C464 in the paracaspase domain
(Figures 3D and S3A), consistent with a
covalent-bond formation between these
two groups. Collectively, the data sug-
gest that MI-2 engages and irreversibly
binds the MALT1 active site.To examine whether MI-2 inhibition of MALT1 is consistent
with irreversible binding kinetics, LZ-MALT1 was preincubated
with different concentrations of MI-2 for 5–80 min followed by
addition of the substrate Ac-LRSR-AMC to determine enzymatic
activity (Figures 3E and S3B). Notably, the percent MALT1
inactivation increased with time, reaching plateaus near the
end of the test, consistent with covalent and irreversible inhi-
bition. Inhibition was concentration dependent, with higher
concentrations showing greater inactivation and faster rates of
saturation. In contrast, the active MI-2 analog MI-2A2, which
does not have the chloromethyl amide group, showed no
evidence of cumulative inhibition of MALT1, consistent with
reversible inhibition. It should be noted that MI-2 reached close
to 100% inhibition, whereas MI-2A2 with a lower IC50 only
reached 50% inhibition (Figure 3E). The irreversible kinetics
might contribute to the more potent effects of MI-2 in cell-based
assays versus its analogs that lack the chloromethyl amide
group and only bind reversibly, as has been noted in the case
of peptidyl halomethyl ketone protease inhibitors (Powers
et al., 2002).
MI-2 Inhibits MALT1 Functions in ABC-DLBCL Cell Lines
Having confirmed MI-2 as a lead compound, we next explored
its effects on MALT1 signaling in ABC-DLBCL cells. We first
examined the impact of MI-2 on cleavage of additional MALT1
substrates such as A20, BCL10, and RELB. Because these
proteins are directed to proteasomal degradation after cleavage
(Coornaert et al., 2008; Hailfinger et al., 2011; Rebeaud et al.,
2008), we used the proteasome inhibitor MG-132 to facilitate
visualization of cleavage products (Figure 4A). HBL-1 andecember 11, 2012 ª2012 Elsevier Inc. 815
Figure 3. MI-2 Directly Interacts with and
Irreversibly Inhibits MALT1
(A) Superposition of the 1H-15N HSQC spectrum
of the apo-MALT1 (red) with the MALT1-MI-2
complex (blue) at a molar ratio of 1:1. The ex-
panded regions highlight interacting residues in
the slow-exchange regime on the NMR timescale
(intermediate 1:0.5 MALT1:MI-2 ratio is shown in
green).
(B) One-dimensional (top) and two-dimensional
(bottom) 1H-13C HSQC NMR spectra of MALT1
(329–728) without (black) and with compounds
MI-2A6, MI-2A7, and MI-2 (red).
(C) LC-MS for MALT1WT and MALT1C464A (amino
acids 329–728) with and without MI-2.
(D) Docked MI-2 (in stick model) on the MALT1
paracaspase domain (in surface representation).
MALT1 is shown in magenta with C464 in yellow.
MI-2 is shown with carbons in yellow, oxygens in
red, nitrogens in blue, and chlorines in green.
(E) LZ-MALT1 was preincubated with the indi-
cated concentrations of MI-2 or MI-2A2 (0–25 mM)
for different durations (5–90 min) before Ac-LRSR-
AMC was added. The graphs represent normal-
ized % inhibition compared to preincubation time.
See also Figure S3.
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MALT1 Inhibitors for ABC-DLBCLTMD8 cell lines were exposed to either MI-2 (2 mM) or vehicle for
30 min followed by 5 mMMG-132 for an additional 1 (lanes 2 and
3) or 2 hr (lanes 4 and 5) in order to allow cleaved forms of MALT1
substrates to accumulate during exposure to MI-2. As expected,
MG-132 exposure revealed the accumulation of A20, BCL10,
and RELB cleavage products due to the constitutive activity
of MALT1 in these DLBCL cells. However, exposure to MI-2
diminished the abundance of cleaved forms and/or increased
the abundance of full-length proteins, consistent with the loss
of MALT1 enzymatic activity (Figure 4A).
MALT1 mediates c-REL translocation to the nucleus following
BCR stimulation (Ferch et al., 2007). Therefore, HBL-1 cells were
exposed to 200 nMMI-2, 50 mMZ-VRPR-FMK (positive control),
or vehicle for 24 hr, followed by c-REL flow cytometry of whole
cells or isolated nuclei. Both MI-2 and Z-VRPR-FMK reduced
nuclear c-REL to a similar extent, without affecting whole-cell
levels of this protein (Figure 4B). To further confirm this result,
we also performed western blots for c-REL and p65 in nuclear
extracts of HBL-1 and TMD8 cells treated for 24 hr with GI50
concentrations of MI-2 (200 nM for HBL-1 and 500 nM for
TMD8). In both cell lines, exposure to MI-2 caused a clear reduc-
tion of nuclear c-REL whereas it did not affect p65 levels (Fig-816 Cancer Cell 22, 812–824, December 11, 2012 ª2012 Elsevier Inc.ure 4C). This selectivity toward c-REL
had also been previously shown in
MALT1 knockout mice and after MALT1
cleavage inhibition by the MALT1 block-
ing peptide Z-VRPR-FMK (Ferch et al.,
2007, 2009; Hailfinger et al., 2011).
Antigen receptor-mediated NF-kB sig-
naling partly depends on MALT1 activity
(Ruefli-Brasse et al., 2003; Ruland et al.,
2003). Hence, we tested the effect of
MI-2 on attenuating NF-kB activationinduced by phorbol 12-myristate 13-acetate (PMA)/ionomycin,
which mimics BCR activation and activates MALT1-dependent
cleavage (Coornaert et al., 2008; Rebeaud et al., 2008). First,
293T cells were transfected with the NF-kB reporter vector
(NF-kB)5-luc2CP-pGL4 (harboring five copies of the NF-kB
consensus-response element and a destabilized firefly lucif-
erase) and TK-pRL control together with plasmids expressing
BCL10 and either MALT1WT or MALT1C464A (inactive mutant).
Exposure to PMA/ionomycin significantly increased luciferase
activity in 293T cells when MALT1WT was transfected, but not
with the mutant MALT1C464A. Pretreatment with MI-2 signifi-
cantly inhibited NF-kB induction by PMA/ionomycin stimulation
similarly to Z-VRPR-FMK, whereas it did not significantly affect
that of MALT1C464A (Figure 4D). HBL-1 cells are reported to
exhibit chronic active B cell receptor signaling with consequent
NF-kB activation (Davis et al., 2010). HBL-1 was transfected
with the reporter construct (NF-kB)5-luc2CP-pGL4 and TK-pRL
control. Treatment with MI-2 promoted a 20% and 50% reduc-
tion in NF-kB reporter activity at 8 and 24 hr, respectively. A
similar result was observed for Z-VRPR-FMK (50 mM) (Figure 4E).
This reduction in NF-kB reporter activity was significant at 24 hr
for MI-2 and the blocking peptide Z-VRPR-FMK.
Figure 4. MI-2 Inhibits MALT1 Signaling in
DLBCL Cells
(A) Western blots for A20, RELB, and BCL10 after
30 min pretreatment with 2 mM MI-2 or vehicle,
followed by proteasome inhibitor MG-132 (5 mM)
treatment for 1 or 2 hr in HBL-1 and TMD8.
Arrowheads indicate cleavage products.
(B) Flow cytometry for c-REL whole cells or iso-
lated nuclei from HBL-1 cells treated with 200 nM
MI-2, 50 mM Z-VRPR-FMK, or vehicle for 24 hr.
(C) c-REL and p65 protein expression in nuclear
extracts of HBL-1 and TMD8 cells treated for 24 hr
with 200 or 500 nM MI-2, respectively.
(D) NF-kB reporter assays in 293T cells trans-
fected with the indicated expression constructs.
Cells were treated for 30 min with 2 mM MI-2,
50 mM Z-VRPR-FMK, or vehicle followed by PMA/
ionomycin for 2 hr. The y axis represents luciferase
fold induction relative to vehicle-treated cells,
normalized to internal control. Statistics, ANOVA,
Bonferroni posttest.
(E) NF-kB reporter assays in HBL-1 cells treated
with 200 nMMI-2, 50 mMZ-VRPR-FMK, or vehicle
for 8 and 24 hr. The y axis represents % luciferase
activity relative to vehicle-treated cells, normalized
to internal control. Statistics, ANOVA, Bonferroni
posttest.
(F) Enrichment of Z-VRPR-FMK-downregulated
genes after MI-2 treatment in HBL-1 and TMD8
cells using GSEA. Normalized enrichment score
(NES) and false discovery rate (FDR) values are
indicated. Top: enrichment score versus relative
position of ranked genes (green tracing); bottom:
fold change (FC) MI-2/vehicle versus relative
position of ranked genes (blue tracing). Experi-
ments were performed in triplicate unless other-
wise specified. Data are mean ± SEM.
See also Figure S4.
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MALT1 Inhibitors for ABC-DLBCLThe impact of MI-2 on NF-kB signaling was further character-
ized by gene expression profiling. For these experiments, the
HBL-1 and TMD8 cell lines were treatedwith GI50 concentrations
of MI-2 (HBL-1, 200 nM; TMD8, 500 nM) or 50 mM Z-VRPR-FMK
for 8 hr, and RNA was extracted for gene expression studies
using oligonucleotide microarrays. Z-VRPR-FMKwas previously
shown to attenuate the NF-kB signature in ABC-DLBCL cell lines
(Hailfinger et al., 2009). MI-2 would be expected to exhibit
a similar profile. For this study, we assigned Z-VRPR-FMK signa-
tures by capturing the top 200 downregulated genes by Z-VRPR-
FMK treatment compared to vehicle for each cell line. We next
performed gene set enrichment analysis (GSEA) of this Z-
VRPR-FMK signature against the differential expression of all
genes preranked by fold change between MI-2- and vehicle-
treated cells for each cell line. The Z-VRPR-FMK signature was
significantly enriched among genes downregulated after MI-2
treatment for both cell lines (Figure 4F). GSEA was next per-
formed using two independent ABC-DLBCL NF-kB gene
expression signatures derived from either OCI-Ly3 and OCI-
Ly10 or HBL-1 cell lines. We observed significant enrichment
of these NF-kB gene sets among genes downregulated after
MI-2 treatment in both cell lines (Figure S4). Collectively, theseCandata suggest that MI-2 suppresses NF-kB activity induced by
MALT1, similar to the effect observed with Z-VRPR-FMK.
MI-2 Selectively Suppresses MALT1-Dependent DLBCL
Cell Lines
To further explore the spectrum ofMI-2-mediatedMALT1-inhibi-
tion effects, we turned to a larger panel of six ABC-DLBCL and
two GCB-DLBCL cell lines (Table S1). Endogenous MALT1
activity was evaluated by western blotting for A20, BCL10, and
CYLD, and NF-kB activation by phospho-IkB-a and total IkB-
a (Figure S5A). Dependence on MALT1 proteolytic activity for
proliferation was tested by 50 mM Z-VRPR-FMK treatment for
48 hr (Figure S5B). As expected, the two GCB-DLBCL cell lines
(OCI-Ly7 and OCI-Ly1) did not display evidence of MALT1 or
NF-kB signaling and did not respond to Z-VRPR-FMK. The
U2932 and HLY1 ABC-DLBCL cell lines harbor mutations in
TAK1 and A20, which activate NF-kB signaling downstream of
MALT1. Hence, these two cell lines displayed relatively little
response to Z-VRPR-FMK. In contrast, the ABC-DLBCL cells
HBL-1, TMD8, OCI-Ly3, and OCI-Ly10 displayed evidence of
MALT1 activity and inhibition of proliferation by Z-VRPR-FMK,
indicating that these four cell lines are MALT1 dependent.cer Cell 22, 812–824, December 11, 2012 ª2012 Elsevier Inc. 817
Figure 5. MI-2 Inhibits Cell Proliferation of MALT1-Dependent DLBCL Cells
(A) Dose-effect graphical representation for eight DLBCL cell lines exposed to MI-2 for 48 hr. Data are mean ± SEM of three independent experiments performed
in triplicate.
(B) Intracellular MI-2 concentration determined by LC-MS in HBL-1 cells treated for 2 hr. The y axis represents MI-2 intracellular concentration. The x axis
represents administered dose of MI-2. Fold-change accumulation in cells is indicated.
(C)CFSEdilutionassay inHBL-1andOCI-Ly1cells after treatmentwithMI-2 for 48, 72, and96hr.Cells (23104)weremeasured;DAPIcellsweregated for analysis.
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of MI-2 (single dose) and cell proliferation was measured at
48 hr using an ATP-based metabolic luminescent assay (Fig-
ure 5A). Growth inhibition by MI-2 was selective for MALT1-
dependent cell lines, whereas the ABC-DLBCLMALT1-indepen-
dent cell lines, U2932 and HLY-1, and the two GCB-DLBCL cell
lines were resistant. The GI50 for MI-2 in HBL-1, TMD8, OCI-
Ly3, and OCI-Ly10 cells was 0.2, 0.5, 0.4, and 0.4 mM, respec-
tively, which is lower than its IC50 in vitro (Figure 1). This is likely
explained by the irreversible binding of MI-2 to MALT1 as shown
in Figure 3, but could also be due to intracellular accumulation of
the compound. Indeed,we observed an 18- to 30-fold increase in
MI-2 intracellular concentration in experiments where HBL-1
cells were exposed to 0.02, 0.2, or 2 mMMI-2 for 2 hr andwashed
three times and MI-2 was measured by LC-MS (Figure 5B). The
intracellular concentration in the 0.2 mM MI-2-treated cells was
5 mM, similar to the calculated in vitro IC50 (Figure 5B). To deter-
mine the kinetics of accumulation of free drug, we measured the
intracellular concentration of MI-2 at the GI50 concentration of
0.2 mM at 30 min and 2, 6, 12, 24, and 48 hr (Figure S5C). By
12 hr, there was virtually no detectable free MI-2 within the cells.
However, after exposure of HBL-1 cells to increasing concentra-
tions of a single dose of MI-2, recovery of cells only started to
become evident after 48 hr (of the 0.2 mMdose level; Figure S5D).
These data suggest that the potent biological effects of MI-2 are
due at least in part to its irreversible binding toMALT1 aidedby its
tendency to concentrate in cells.
To explore in more detail the biological effects of MALT1 inhi-
bition, HBL-1, TMD8, OCI-Ly10, and the GCB-DLBCL cell line
OCI-Ly1 were treated with increasing concentrations of MI-2.
Cell proliferation was examined using the 5-(and 6)-carboxy-
fluorescein diacetate succinimidyl ester (CFSE) dilution assay
by flow cytometry on viable cells at 48, 72, and 96 hr. MI-2
substantially inhibited proliferation in HBL-1, TMD8, and OCI-
Ly10 whereas it did not affect OCI-Ly1 (Figures 5C and S5E).
Using BrdU incorporation-DAPI (40,6-diamidino-2-phenylindole)
staining and flow cytometry to assess the cell cycle, it
was evident that MI-2 induced a dose-dependent decrease in
S phase, with a reciprocal increment in the proportion of cells
in G1-0 and sub-G0 (Figure 5D). To determine whether MALT1
inhibitors induced apoptosis, the ABC-DLBCL cell lines HBL-1
and TMD8 were treated daily with MI-2 at their respective GI25
and GI50, and the control OCI-Ly1 cell line at the higher doses
was used for TMD8. Trypan blue exclusion and apoptosis as-
sessed by Annexin V+ DAPI flow cytometry was measured
every 48 hr for a period of 14 days. Whereas MI-2 had no effect
on OCI-Ly1 cells, it profoundly suppressed both HBL-1 and
TMD8 cells, with the former exhibiting earlier and higher abun-
dance of apoptotic cells (Figure 5E). Using the more sensitive
caspase-3/7 cleavage assay, we observed evidence of dose-
dependent apoptosis within 48 hr in both ABC-DLBCL cell lines
(Figure S5F). Hence, MI-2 powerfully suppresses the growth and
survival of ABC-DLBCL cell lines.(D) BrdU pulse-labeled HBL-1 cells treated for 24 and 48 hr with MI-2 were analyz
for vehicle and each of the concentrations assayed. Data are mean ± SD of two
(E) Apoptosis time course in cell lines treated withMI-2 every 24 hr. Cells were cou
48 hr for a period of 14 days. Left y axis, % cell number relative to vehicle for ea
See also Table S1 and Figure S5.
CanCompound MI-2 Is Nontoxic to Animals
To determine its suitability as aMALT1 lead compound for in vivo
studies, we examined whether MI-2 induced toxic effects in
mice. Five C57BL/6 mice were exposed to daily intraperitoneal
(IP) administration of increasing doses of MI-2 ranging from
0.05 to 25 mg/kg over the course of 10 days to a cumulative
dose of 51.1 mg/kg, and another five mice were exposed to
vehicle only (5% DMSO, n = 5) (Figure 6A, toxicity 1). There
was no evidence of lethargy, weight loss (Figure 6B, toxicity 1),
or other physical indicators of sickness. To ascertain whether
the maximal administered dose of 25 mg/kg is safe in a 14 day
schedule, we exposed ten mice to daily IP administration of
25 mg/kg of MI-2 over 14 days to a cumulative dose of
350 mg/kg, using as controls five mice injected with vehicle
only (Figure 6A, toxicity 2). Five mice were sacrificed after the
14 day course of MI-2 administration (together with the five
controls) and the other five mice were sacrificed after a 10 day
washout period to assess delayed toxicity. No toxic effects or
other indicators of sickness, including weight loss (Figure 6B,
toxicity 2) or tissue damage (macroscopic or microscopic),
were noted (Figure 6C). Brain, heart, lung, liver, kidney, bowel,
spleen, thymus, and bone marrow tissues were examined.
Bone marrow was normocellular with trilineage maturing hema-
topoiesis. Myeloid-to-erythroid ratio was 4–5:1. Megakaryo-
cytes were normal in number and distribution. There was no
fibrosis or increased number of blasts or lymphocytes. Complete
peripheral blood counts, biochemistry, and liver function tests
were normal (Table S2), These studies established the safety
of MI-2 for use in antilymphoma efficacy studies.
MI-2 Suppresses Human ABC-DLBCL Xenografts
and Primary Human DLBCLs Ex Vivo
In order to determine whether MI-2 could suppress DLBCLs
in vivo, we engrafted HBL-1 and TMD8 (MALT1-dependent)
and OCI-Ly1 (MALT1-independent) DLBCL cells into the right
flank region of nonobese diabetic/severe combined immuno-
deficiency (NOD-SCID) mice. Once tumors reached an average
of 120 mm3 in volume, mice were randomized to receive IP
injection of MI-2 25 mg/kg/day or vehicle (5% DMSO). Animals
were sacrificed 24 hr after the 14th injection. Remarkably, MI-2
profoundly suppressed the growth of both the TMD8 and
HBL-1 ABC-DLBCL xenografts versus vehicle, whereas it had
no effect on the growth of OCI-Ly1 tumors (Figure 7A). The fact
that OCI-Ly1 tumors were unaffected suggests that MI-2 activity
is due to its effects on lymphoma cells rather than the host
microenvironment. Histological examination using the TUNEL
assay to detect apoptotic cells showed a significant increase
in apoptotic cells in MI-2-treated HBL-1 and TMD8 xenografts
relative to vehicle but not in OCI-Ly1 xenografts (Figures 7B
and S6A). We also observed a significant decrease in prolife-
ration as measured by Ki-67 staining in HBL-1 and TMD8
xenografts compared to vehicle, but observed no difference in
OCI-Ly1 xenografts (Figures 7C and S6B). To evaluate the effected by flow cytometry. The graph shows the% of cells for each cell-cycle phase
independent experiments.
nted using trypan blue and apoptosis was assessed by Annexin V+ DAPI every
ch time point. Right y axis, % apoptotic cells for each time point.
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Figure 6. MI-2 Is Nontoxic to Animals
(A) Dose scheme for toxicity 1 (increasing daily
dose) and toxicity 2 (same daily dose) experiments
show daily and cumulative doses for each exper-
iment.
(B) The y axis depicts mean ± SEM body weight of
animals studied in both the incremental and
cumulative dose schemes. Toxicity 1, p = 0.59
t test; toxicity 2, p = 0.52 t test.
(C) H&E staining for the indicated tissues in
animals treated with vehicle, MI-2 25 mg/kg daily
for 14 days, or MI-2 25 mg/kg daily for 14 days
followed by a 10 day washout.
See also Table S2.
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immunofluorescence was performed in paraffinized tumor
sections. Consistent with data shown in Figures 4B and 4C,
MI-2-treated tumors exhibited reduced c-REL nuclear protein
(Figures 7D and S6C). Therefore, the MI-2 small-molecule
MALT1 inhibitor specifically suppresses proliferation, survival,
and NF-kB activity in ABC-DLBCLs in vivo in a lymphoma cell-
autonomous manner.
Finally, to determine whether MI-2 could also suppress
primary human DLBCLs, we obtained single-cell suspensions
from lymph node biopsies of five DLBCL patients for whom their
GCB versus non-GCB status could be ascertained by immuno-
histochemistry using the Hans criteria (Hans et al., 2004), as
a surrogate for GCB versus ABC classification. Lymphoma cells820 Cancer Cell 22, 812–824, December 11, 2012 ª2012 Elsevier Inc.were isolated and exposed to 0.8 mMMI-
2 or vehicle in four replicates. After 48 hr
exposure, cell number and viability were
determined using trypan blue. Notably,
two of the non-GCB cases responded to
MI-2 (p = 0.04 and 0.003 versus vehicle),
whereasnoneof theGCBsdid (Figure 7E).
One of the non-GCB cases did not
respond to MI-2; perhaps this case was
not accurately classified by Hans’s
criteria. Overall, these studies indicate
that therapeutic targeting of MALT1 using
the MI-2 small-molecule inhibitor has
powerful suppressive effects on human
ABC-DLBCL cells and warrants transla-
tion for use in clinical trials.
DISCUSSION
CBM complex signaling is constitutively
active in a subset of ABC-DLBCLs due
to somatic mutations of various genes
leading to constitutive MALT1 signaling
and NF-kB activation (Davis et al.,
2010). The catalytic activity of MALT1 is
well defined and involves substrate fea-
tures such as peptide length and amino
acid composition and position (Hach-
mann et al., 2012). Purified MALT1 is not
very active in solution, because it ispresent as a monomer instead of its active dimeric form. Dimer-
ization can be induced by high-salt concentrations, 1 M sodium
citrate (Boatright et al., 2003). However, these high-salt condi-
tions are nonphysiological and unsuitable for screening physio-
logically relevant small-molecule inhibitors. Use of a constitu-
tively dimeric form of MALT1 enabled us to screen and identify
potential inhibitors. Among these, MI-2 was found to be a potent,
selective, and irreversible MALT1 inhibitor, analogous to
protease inhibitor drugs such as telaprevir against the NS3/4A
protease of hepatitis C virus (Klibanov et al., 2011), the protea-
some inhibitor carfilzomib (Genin et al., 2010), and others
(Powers et al., 2002). Although the peptide inhibitor Z-VRPR-
FMK has been useful as a research tool, it is not suitable as
a MALT1 therapeutic agent given its relatively large size, charge,
Figure 7. MI-2 Suppresses ABC-DLBCLs
In Vivo and Primary Human DLBCL Ex Vivo
(A) Tumor growth curve for HBL-1, TMD8, and
OCI-Ly1 xenografts in NOD-SCID mice treated
with 25 mg/kg/day MI-2 or the same volume of
vehicle for 14 consecutive days. Statistics, paired
t test.
(B) TUNEL+ staining in histologic sections of
HBL-1, TMD8, and OCI-Ly1 xenografts. The y axis
represents the number of TUNEL+ cells per ten
high-power fields (HPFs; n = 5 tumors/treatment,
n = 3 for HBL-1). Statistics, t test.
(C) Ki-67 immunohistochemistry staining of
xenografted HBL-1, TMD8, and OCI-Ly1 tumor
sections. The y axis represents Ki-67+ cells per
high-power field (5 HPFs/tumor for n = 5 where
analyzed for each treatment, n = 3 for HBL-1).
Statistics, t test.
(D) Immunohistochemical detection of c-REL in
sections from HBL-1 xenografts exposed to MI-2
or vehicle. Insets are 23 digital amplification.
Representative image of three HPFs analyzed for
n = 3 tumors stained for each treatment.
(E) Viability assays were performed in quadrupli-
cate in primary human DLBCL patient samples
treated for 48 hr with 0.8 mMMI-2 or vehicle. The y
axis represents % of viable cells normalized to
vehicle. Data are presented as mean ± SEM for
all panels.
See also Figure S6.
Cancer Cell
MALT1 Inhibitors for ABC-DLBCLand consequent lower cell permeability. Accordingly, MI-2 dis-
played superior activity in cell-based assays with excellent cell
penetration and indeed featured high concentration within cells,
and yet was still highly selective for MALT1 versus other cas-
pases. Notably, a selective and irreversible small-molecule
inhibitor of the tyrosine kinase BTK, PCI-32765 (ibrutinib),
is currently under clinical development in patients with B cell
non-Hodgkin’s lymphoma (Honigberg et al., 2010). Irreversibility
of MI-2 may provide pharmacokinetic advantages. As ABC-
DLBCLs have chronically active BCR signaling, prolonged
suppression of MALT1 cleavage would likely be necessary for
maximal antilymphoma activity. Using an irreversible inhibitor,
activity will only return when new enzyme is synthesized. This
may allow drugs to be effective at a lower plasma concentration,
thus reducing dosing level and frequency, limiting the require-
ment for a long plasma half-life without compromising efficacy,
andminimizing potential toxic effects related to prolonged expo-
sure to circulating drugs. Indeed, our detailed studies indicated
that MI-2 was nontoxic in animals. This result is consistent with
the fact that MALT1 is the only paracaspase in humans and
that MALT1-deficient mice are relatively healthy (Ruefli-Brasse
et al., 2003; Ruland et al., 2003).Cancer Cell 22, 812–824, DChronic activation of the BCR pathway
in ABC-DLBCL is mediated by several
different mechanisms, many of them
upstream of MALT1. ABC-DLBCL is ad-
dicted to this pathway and is often specif-
ically addicted to MALT1 cleavage
activity (Ferch et al., 2009; Hailfinger
et al., 2009; Ngo et al., 2006). Notably,MI-2 selectively killed ABC-DLBCL cell lines with CD79A/B,
CARMA1, and/or MYD88 mutations but not those occurring in
proteins downstream of MALT1, including those with A20 homo-
zygous deletion or TAK1 mutation. These findings underline the
importance of targeted resequencing of recurrently mutated
alleles in lymphoma for the rational deployment of targeted ther-
apeutics. Although the full spectrum of lymphomas that can be
targeted with MALT1 inhibitors is not fully clear yet, using an
ex vivo system we were able to show that primary human non-
GCB-DLBCL specimens are also addicted to MALT1 and are
suppressed by MI-2.
As single agents are generally not curative and rapidly
generate resistance (Misale et al., 2012), there is a growing
interest in combinatorial-targeted therapy. Rational combination
of MALT1 cleavage inhibition could include a combination with
tyrosine kinase inhibitors targeting the Src family (dasatinib,
saracatinib, bosutinib, and KX01), SYK (fostamatinib disodium),
or BTK (PCI-32765). These drugs would likely synergize with
MALT1 cleavage inhibition of NF-kB by further inhibiting BCR
signaling, including mitogen-activated protein kinases and
phosphatidylinositol 3-kinase (Lim et al., 2012). Protein kinase
C (PKC) inhibition would also be a potentially beneficialecember 11, 2012 ª2012 Elsevier Inc. 821
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MALT1 Inhibitors for ABC-DLBCLcombination, as it could further inhibit the NF-kB pathway,
including those activities dependent on MALT1 but independent
of its proteolytic activity. The PKC inhibitor sotrastaurin, in clin-
ical trials for prevention of transplantation rejection and treat-
ment of psoriasis (Manicassamy, 2009; Matz et al., 2011), has
been recently shown to inhibit growth of ABC-DLBCL xeno-
grafted tumors (Naylor et al., 2011), pointing to its potential use
as an antilymphoma therapy for this lymphoma subtype. ABC-
DLBCLs also feature BCL6 translocation, SPI-B amplification,
or PRDM1 deletion or mutation (Lenz and Staudt, 2010). BCL6
inhibitors promote apoptosis and cell-cycle arrest through
release of critical checkpoint genes (Cerchietti et al., 2009,
2010a; Polo et al., 2004). Combination of MI-2 and BCL6 inhi-
bitors would thus suppress two critical pathways in ABC-
DLBCLs (BCL6 and NF-kB), potentially leading to therapeutic
synergy. Taken together, the results reported here identify MI-2
as a lead compound targeting MALT1 and demonstrate the
significance, safety, and efficacy of MALT1 as a therapeutic
target and MI-2 as a therapeutic agent for the treatment of
aggressive non-Hodgkin’s lymphomas that are both dependent
on NF-kB signals and resistant to conventional chemothera-
peutic regimens.
EXPERIMENTAL PROCEDURES
Detailed experimental procedures are presented in Supplemental Experi-
mental Procedures.
High-Throughput Screening for MALT1 Proteolytic Activity
Inhibitors
Ac-LRSR-AMC was used as substrate and reactions were measured with
excitation/emission wavelengths of 360/465 nm. Two time points were
measured for each reaction to eliminate false positives due to compound
autofluorescence. The final percent inhibition was calculated with the
formula {[fluorescencetest compound (T2T1)  fluorescenceneg ctrl (T2T1)]/
[fluorescencepos ctrl (T2T1) – fluorescenceneg ctrl (T2T1)]} 3 100, where Z-
VRPR-FMK (300 nM) was used as positive control and buffer only as negative
control. The positive hits were validated in concentration-response experi-
ments within a dose range of 0.122–62.5 mM to determine IC50 of the
compounds. Activity was validated using recombinant full-length wild-type
MALT1.
Growth-Inhibition Determination
Cell proliferation was determined by ATP quantification using a luminescent
method (CellTiter-Glo; Promega) and trypan blue dye exclusion. Standard
curves for each cell line were calculated by plotting the cell number (deter-
mined using trypan blue) against their luminescence values, and cell number
was calculated accordingly. Cell viability in drug-treated cells was normalized
to their respective controls (fractional viability), and results are given as
1-fractional viability. CompuSyn software (Biosoft) was used to determine
GI25 and GI50 values.
Mouse Xenograft Experiments
Eight-week-old male SCID NOD.CB17-Prkdcscid/J mice were purchased from
Jackson Laboratories and housed in a clean environment. Mice were subcu-
taneously injected with low-passage 107 human HBL-1, TMD8, or OCI-Ly1
cells in 50% Matrigel. Treatment was initiated when tumors reached an
average size of 120 mm3. MI-2 was reconstituted in DMSO and stored
at 80C until used and was administered by intraperitoneal injection. Tumor
volume was monitored by digital calipering three times a week and calculated
using the formula (smallest diameter2 3 largest diameter)/2. All procedures
involving animals followed National Institutes of Health protocols and were
approved by the Animal Institute Committee of the Weill Cornell Medical
College of Cornell University.822 Cancer Cell 22, 812–824, December 11, 2012 ª2012 Elsevier IncPrimary Cells
Patient-deidentified tissues were obtained in accordance with the guidelines
and approval of the University of Navarra Institutional and Weill Cornell
Medical College Review Boards. Only discarded leftover tissue after diagnosis
was rendered was utilized for research, in agreement with institutional review
board protocol. Patient samples were processed as previously described
(Cerchietti et al., 2010b). Briefly, single-cell suspensions from lymph node
biopsies were obtained by physical disruption of tissues followed by cell-
density gradient separation. Cell number and viability were determined by
trypan blue exclusion. Primary DLBCL cells were cultured in 96-well plates.
Cells were grown in RPMI medium with 20% FBS supplemented with antibi-
otics for 48 hr. Cells were exposed to 0.8 mM MI-2 (1 mM for Pt.2) or control
(DMSO) in quadruplicate. After 48 hr of exposure, viability was determined
by using trypan blue (Sigma). All samples were normalized to their own repli-
cate control.
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